Episode Details

Moderna’s stock soared more than double after revealing breakthrough results for its melanoma vaccine, intismeran, when paired with Merck’s Keytruda—showing it can stop cancer from returning or spreading in high-risk patients. Experts hail this as a game-changing leap in personalized cancer treatment, offering new hope for long-term remission and reshaping future standards of care.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/4bda946505f533cb